These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 16262910)
21. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Seeger JD; Kong SX; Schumock GT Pharmacotherapy; 1998; 18(6):1284-9. PubMed ID: 9855328 [TBL] [Abstract][Full Text] [Related]
22. Platelet-activating factor antagonism and streptokinase-induced hypotension in clinical acute myocardial infarction. Taylor R; Fatovich D; Hitchcock T; Morrison C; Curtis L Clin Sci (Lond); 2001 Jun; 100(6):601-7. PubMed ID: 11352774 [TBL] [Abstract][Full Text] [Related]
23. Overview of adverse reactions to nefopam: an analysis of the French Pharmacovigilance database. Durrieu G; Olivier P; Bagheri H; Montastruc JL; Fundam Clin Pharmacol; 2007 Oct; 21(5):555-8. PubMed ID: 17868209 [TBL] [Abstract][Full Text] [Related]
24. [Streptokinase as routine treatment in acute myocardial infarction. The effect on pain, arrhythmias and mortality assessed by a historical cohort study]. Christensen JH; Sørensen HT; Nielsen FE; Ravn L; Rasmussen SE Ugeskr Laeger; 1991 Dec; 153(49):3473-6. PubMed ID: 1776180 [TBL] [Abstract][Full Text] [Related]
25. [Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?]. Silva LA; Ribeiro E; Carneiro RC; Kaissar S; Reis Filho A; Torossian SP; Tavares JR; Buffolo E; Amino JG; Duprat Filho R Arq Bras Cardiol; 1990 Jul; 55(1):13-7. PubMed ID: 2127353 [TBL] [Abstract][Full Text] [Related]
26. Clinical characteristics and risk assessment of ST-segment elevation myocardial infarction patients of an Iranian referral center. Khalili H; Talasaz AH; Jenab Y; Salarifar M J Cardiovasc Med (Hagerstown); 2012 Nov; 13(11):708-15. PubMed ID: 22914305 [TBL] [Abstract][Full Text] [Related]
27. Is haemorrhagic myocardial infarction more common with streptokinase? Naik AM; Nabar AA; Lokhandwala YY; Kulkarni HL; Deshpande JR; Sivaraman A Indian Heart J; 1997; 49(4):387-90. PubMed ID: 9358661 [TBL] [Abstract][Full Text] [Related]
28. New guideline for tramadol usage following adverse drug reactions reported to the Iranian Pharmacovigilance Center. Gholami K; Shalviri G; Zarbakhsh A; Daryabari N; Yousefian S Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):229-37. PubMed ID: 17063533 [TBL] [Abstract][Full Text] [Related]
29. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Bender S; Grohmann R; Engel RR; Degner D; Dittmann-Balcar A; Rüther E Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S46-53. PubMed ID: 15052514 [TBL] [Abstract][Full Text] [Related]
30. The importance of monitoring adverse drug reactions in pediatric patients: the results of a national surveillance program in Italy. Carnovale C; Brusadelli T; Zuccotti G; Beretta S; Sullo MG; Capuano A; Rossi F; Moschini M; Mugelli A; Vannacci A; Laterza M; Clementi E; Radice S; Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S1-8. PubMed ID: 25171154 [TBL] [Abstract][Full Text] [Related]
31. [Pharmacovigilance IV. The institutional experience]. Hernández Santillán DL; Rodríguez Betancourt L; Jasso Gutiérrez L Rev Med Inst Mex Seguro Soc; 2005; 43(3):257-66. PubMed ID: 16138461 [TBL] [Abstract][Full Text] [Related]
32. Streptokinase for acute myocardial infarction in the elderly. Qureshi AE; Jafri NA; Noeman A; Yasmin S; Khalil H J Ayub Med Coll Abbottabad; 2014; 26(4):535-8. PubMed ID: 25672182 [TBL] [Abstract][Full Text] [Related]
33. Addressing adverse events through clinical indicators. Portelli R; Collopy B; Desmond P J Qual Clin Pract; 1999 Jun; 19(2):79-83. PubMed ID: 10408746 [TBL] [Abstract][Full Text] [Related]
34. Optimizing of Nutrients for High Level Expression of Recombinant Streptokinase Using pET32a Expression System. Mahmoudi S; Abtahi H; Bahador A; Mosayebi G; Salmanian AH; Teymuri M Maedica (Bucur); 2012 Sep; 7(3):241-6. PubMed ID: 23400422 [TBL] [Abstract][Full Text] [Related]
35. Spontaneous reporting of adverse drug reactions in Cuba: integrating continuous education, training and research in a network approach. Debesa F; Jiménez G; Figueras A; Diogène E; Pérez Peña J; Avila J; Laporte JR Br J Clin Pharmacol; 2002 Sep; 54(3):335-6. PubMed ID: 12236857 [No Abstract] [Full Text] [Related]
36. The Streptokinase Therapy Complications and its Associated Risk Factors in Patients with Acute ST Elevation Myocardial Infarction. Aslanabadi N; Safaie N; Talebi F; Dousti S; Entezari-Maleki T Iran J Pharm Res; 2018; 17(Suppl):53-63. PubMed ID: 29796029 [TBL] [Abstract][Full Text] [Related]
38. Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS). Koh Y; Yap CW; Li SC J Am Med Inform Assoc; 2010; 17(6):720-2. PubMed ID: 20962137 [TBL] [Abstract][Full Text] [Related]
39. History of streptokinase use in acute myocardial infarction. Cáceres-Lóriga FM Tex Heart Inst J; 2008; 35(1):91. PubMed ID: 18427671 [No Abstract] [Full Text] [Related]